News-Medical.Net22h
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Life Science Sweden3d
Gilead’s Capsid Revolution Meets Our Capsid Solutions | Sino Biological
LEN is a first-in-class, long-acting HIV-1 capsid inhibitor that disrupts multiple stages of the viral replication cycle. By ...
Credence Research Inc.: Microplates Market to Reach USD 1,301.08 million by 2032, Growing at an 4.50% CAGR - Credence Research
The Global Microplates Market is experiencing steady growth, driven by the increasing adoption of high-throughput screening (HTS) in drug discovery ...
Microplates Market to Reach USD 1,301.08 million by 2032, Growing at an 4.50% CAGR - Credence Research
The Global Microplates Market is experiencing steady growth, driven by the increasing adoption of high-throughput screening ...